Benefit and risk information for medications in multiple sclerosis

Not Applicable

Completed

• Conditions: Multiple sclerosis; Nervous System Diseases

• Registration Number: ISRCTN17318966
• Lead Sponsor: Royal Holloway, University of London

Brief Summary

2021 results in https://pubmed.ncbi.nlm.nih.gov/33513520/ (added 01/02/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-26
• Study Completion: 2017-03-01
• Last Update Posted: 16 February 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Diagnosis of relapsing-remitting multiple sclerosis (RRMS) by a consultant neurologist to best current criteria (i.e. not clinically isolated syndrome (CIS), likely Polman et al., 2011)
2. Able and willing to give informed consent
3. Able to meet tasks demands of study in terms of sensorimotor abilities
4. Ages 18 to 60

Exclusion Criteria

1. Significant change in medication in last 4 weeks
2. Relapse recovery within last 4 weeks
3. Significant psychiatric history/condition
4. Significant medical condition (other than MS), personal or social circumstances likely to influence study participation

Study & Design

• Study Type: Interventional
• Study Design: Not specified